The EURORDIS Winter School on Scientific Innovation and Translational Research consists of one week face-to-face training held in Paris in March and the training modules below, which are available online for anyone to use for free.
EURORDIS launched the training with the aim of deepening patient representatives’ understanding of how pre-clinical research translates into real benefits for rare disease patients.
The training equips participants with knowledge and skills so they are empowered to effectively participate in discussions with the researchers, policy makers and companies responsible for research or research infrastructures.
Expert speakers and researchers from across Europe deliver the face-to-face training sessions.
The first edition of the face-to-face training of the EURORDIS Winter School was held in March 2018 in Paris. It covered topics including the history of genetics, diagnostics, new technologies in gene therapy, and drug repurposing and included laboratory visits.
EURORDIS Winter School 2019 – Apply now
The next on-site training will take place 11-15 March 2019 at the Imagine Institute in Paris. Apply now to take part in a week of face-to-face training, applications close 15 September.
Applicants will be notified of the outcome of their application by mid October.
Take part in free online training
Learn more about rare disease research at a time and place that suits you! Take the free online modules below. Each module includes a lesson and quiz.
The below online modules are from the first edition of the EURORDIS Winter School. Full online modules will be developed following the 2019 edition of the EURORDIS Winter School. The conditions of use for all EURORDIS training have been licensed with Creative Commons.
30 patient organisations and European Patient Advocacy Groups (ePAGs) from around Europe travelled to Paris to participate in the first EURORDIS Winter School.
The 2018 and 2019 editions of the EURORDIS Winter School will be financed through the EU-funded Solve-RD project, of which EURORDIS is a partner.